Evotec SE (EVT.DE) has a MoatMap StockRank of 51/100 based on Quality (36/100), Value (63/100), and Momentum (38/100) factor scores. The current signal is HOLD. Despite operating in the CDMO space, Evotec is a turnaround story plagued by operational disruptions, cyberattacks, and management turnover, violating our rule against turnarounds.
Evotec SE is a global drug discovery and development alliance company partnering with major pharmaceutical and biotechnology firms. Its competitive moat lies in its proprietary, end-to-end technological platforms, extensive scientific data libraries, and high-throughput screening capabilities. Evotec operates as an industry-leading partner, offering a unique risk-sharing business model that includes milestone payments and future product royalties.
| Price | $5.36 |
| Market Cap | $1.1B |
| P/E (Forward) | -36.86 |
| Price/Book | 1.31 |
| Return on Equity | -24.1% |
| Return on Invested Capital | -5.4% |
| Debt/Equity | 55.38 |
| Gross Margin | 10.7% |
| Operating Margin | -29.6% |
| Revenue Growth | -21.7% |
| Free Cash Flow | $135M |
Evotec SE operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Germany).